soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm Reduces CV Events in T2DM – (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine 🧪 T2DM + ASCVD/CKD 💊 Oral semaglutide 14 mg vs placebo 📉 soul trial oral semaglutide cardiovascular

Description

Prescriptions for medications such as Ozempic and Wegovy have climbed rapidly in Australia in recent years, reflecting broader global trends

Simple metabolic reset found to prevent weight rebound after discontinuing GLP-1 drugs Minimally invasive endoscopic procedure may offer lasting weight loss maintenance, scientists say Bookmark CommentsGo to comments A simple outpatient procedure may provide a majority of people who discontinue popular weight-loss drugs a way to prevent regaining their lost pounds, scientists reveal in a new study

Semaglutide is available in two popular brand-name injections, which include: Ozempic Ozempic is FDA-approved for individuals with type 2 diabetes to help manage high blood sugar levels and lose weight

Authors Samuel Gratzl, PhD, Patricia J Rodriguez, PhD, MPH, Brianna M Goodwin Cartwright, MS Charlotte Baker, DrPH, MPH, CPH , Nicholas L Stucky, MD, PhD Accessed in December 2024 via [8] University of California- San Diego